IntroductionPhysicians are at much higher risk for burnout, depression, and suicide than their non-medical peers. One of the working groups from the May 2017 Resident Wellness Consensus Summit (RWCS) addressed this issue through the development of a longitudinal residency curriculum to address resident wellness and burnout.MethodsA 30-person (27 residents, three attending physicians) Wellness Curriculum Development workgroup developed the curriculum in two phases. In the first phase, the workgroup worked asynchronously in the Wellness Think Tank – an online resident community – conducting a literature review to identify 10 core topics. In the second phase, the workgroup expanded to include residents outside the Wellness Think Tank at the live RWCS event to identify gaps in the curriculum. This resulted in an additional seven core topics.ResultsSeventeen foundational topics served as the framework for the longitudinal resident wellness curriculum. The curriculum includes a two-module introduction to wellness; a seven-module “Self-Care Series” focusing on the appropriate structure of wellness activities and everyday necessities that promote physician wellness; a two-module section on physician suicide and self-help; a four-module “Clinical Care Series” focusing on delivering bad news, navigating difficult patient encounters, dealing with difficult consultants and staff members, and debriefing traumatic events in the emergency department; wellness in the workplace; and dealing with medical errors and shame.ConclusionThe resident wellness curriculum, derived from an evidence-based approach and input of residents from the Wellness Think Tank and the RWCS event, provides a guiding framework for residency programs in emergency medicine and potentially other specialties to improve physician wellness and promote a culture of wellness.

No abstract

No abstract

e45 (UGT) and is a substrate of P-glycoprotein (P-gp), coded by UGT and the ATP-binding cassette (ABCB1) genes respectively Methods: We assessed the effect of genetic variability in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African tuberculosis patients. Genotypes for selected UGT1A and ABCB1 SNPS were determined using a TaqMan ® Genotyping OpenArray™, except for rs8175347 where a high resolution melt (HRM) analysis was used to measure TA repeats. A nonlinear mixed-effects model was used to describe moxifloxacin pharmacokinetics. Results: We determined the frequency of genetic variability in UGT1A and ABCB1 in 172 patients. Genotypes of UGT1A SNP's, rs8175347 and rs3755319 were significantly associated with changes in moxifloxacin pharmacokinetic parameters (clearance (CL) and bioavailability). Individuals with the AC or AA genotype for rs3755319 had on average 12.6% higher moxifloxacin clearance and lower AUC compared to individuals with the CC genotype (p = 0.021). TA repeats within the TATA box of the promoter region, showed donors that had TA 5/6 repeats within rs8175347 SNP had a significantly lower clearance and higher bioavailability associated with an approximately 32% increase in AUC compared to TA 6/6, 6/7 and 7/8 repeats (p= 0.001). Genotypes of the ABCB1 SNP rs2032582 were significantly associated with 40% reduced pre-hepatic bioavailability lower AUC in individuals with the CA genotype.